𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Active immunization of homosexual men using a recombinant hepatitis B vaccine

✍ Scribed by Prof. Dr. Georg Hess; Siegbert Rossol; Rita Voth; Darline Cheatham-Speth; Ralf Clemens; Karl-Hermann Meyer Zum Büschenfelde

Book ID
102378914
Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
329 KB
Volume
29
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty homosexual men [13 anti-human immunodeficiency virus (HIV)-positive, seven anti-HIV negative] without HBsAg, anti-HBs, and anti-HBc were vaccinated with three 20 micrograms doses of a recombinant hepatitis B vaccine. All anti-HIV-positive homosexuals were nonresponders independent of the initial number of CD4-positive cells. Among seven anti-HIV-negative individuals, five responded. After three doses of the vaccine, CD4-positive cells fell in anti-HIV positive individuals by 22.4%. A similar fall in CD4-positive cells of an average 24.9% was noted in 17 matching, but nonvaccinated, anti-HIV-positive homosexuals. The study indicates that the efficacy of vaccination in anti-HIV-positive individuals is questionable. There is, however, no evidence that vaccination against hepatitis B might be harmful to anti-HIV-positive subjects.

📜 SIMILAR VOLUMES

Diminished response to recombinant hepat
Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis
✍ Richard H. T. Loke; Dr. Iain M. Murray-Lyon; John C. Coleman; Brian A. Evans; Ar 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB

## Abstract Three doses of a recombinant DNA HBV vaccine (MSD) were given to healthy male homosexuals. Seventy‐eight out of 104 (77.6%) participants had detectable antibody (anti‐HBs) two months after the third dose. Seroconversion occurred in only 9 out of 27 subjects (33.3%) who were anti‐HIV pos

Safety and immunogenicity of a recombina
Safety and immunogenicity of a recombinant hepatitis B vaccine
✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.

Characterization of a human monoclonal a
Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine
✍ R.A. Heijtink; J. Kruining; P. van Bergen; S. de Rave; J. van Hattum; M. Schutte 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasmaderived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBs